New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

In the microscopic world of bacteria, gene transfer is a powerful mechanism that can alter cellular function, drive antibiotic resistance and even shape entire ecosystems.

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Two recent UPC decisions have provided some guidance on the admissibility and reasonableness of auxiliary requests in revocation actions. The ...

On February 12, 2025, the United States District Court for the District of Delaware denied defendant Parse Biosciences’s (“Parse”) motions for ...

Sand Hill Road Host Scott McGrew spoke with Jim Tananbaum to learn more about how artificial intelligence is fueling ...

Parse’s latest innovations include the recent launch of their Evercode Penta kit, the largest ever single cell sequencing kit that allows researchers to look at up to 5 Million cells in a single ...

This comes on the heels of Parse invalidating the patents that 10x Genomics had asserted against ... novel approach with advantages over existing methods such as ATAC-seq and will deliver higher ...

10x Genomics has a fifty-two week low of $9.77 and a fifty-two week high of $45.60. The firm’s 50 day moving average price is $13.90 and its 200 day moving average price is $16.67. Get 10x ...

Woese Institute for Genomic Biology developed a CRISPR-enriched metagenomics method for the enhanced surveillance of antibiotic resistance genes, ARGs, in wastewater. While antibiotics are ...